| Literature DB >> 25628518 |
Shi Qinghong1, Gao Shen1, Song Lina1, Zhao Yueming2, Li Xiaoou3, Wu Jianlin4, He Chengyan1, Li Hongjun1, Zhao Haifeng5.
Abstract
BACKGROUND: Chemoresistance remains a significant challenge in chronic myelogenous leukemia (CML) management, which is one of the most critical prognostic factors. Elucidation the molecular mechanisms underlying the resistance to chemoresistance may lead to better clinical outcomes.Entities:
Year: 2015 PMID: 25628518 PMCID: PMC4307195 DOI: 10.1186/s12953-014-0057-y
Source DB: PubMed Journal: Proteome Sci ISSN: 1477-5956 Impact factor: 2.480
Figure 1Cell proliferation assays for both K562/A02 and K562 cultured in the presence or absence of doxorubicin.
Figure 2A group of pairs of protein 2-D maps of doxorubicin-resistant myelogenous leukemia cell line K562/A02 (left) and its parental control cell line K562 (right) with sample loading of 0.6 mg protein each. The isoelectric focusing was carried on 17 cm IPG strips with a pH range of either 3.9-5.1 (A, B), 4.7-5.9 (C, D), 5.5-6.7 (E, F) or 6.3-8.3 (G, H). For the second dimension, acrylamide gels of 12.5% were used. The gels were stained by Colloidal Coomassie blue G-250 over night. Numbers associated with the spots on the gel images refer to the identified proteins listed in Table 1.
Summary of differentially expressed proteins
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Proteins with increasing spot intensity | ||||||||
| 1 | P08107 | Heat shock 70 kDa protein 1A/1B | Unfolded protein binding | PMF, MS/MS | 8 | 5.47/70.05 | 98 | 2.03 (2.55)* |
| 2 | P17987 | T-complex protein 1 subunit alpha | Molecular chaperonin | MS/MS | 17 | 5.80/60.34 | 103 | 3.91 |
| 3 | P50453 | Serpin B9 | Cysteine-type endopeptidase inhibitor activity involved in apoptotic process | PMF, MS/MS | 4 | 5.61/42.40 | 67 | 2.34 |
| 4 | P08670 | Vimentin | Double-stranded RNA binding | PMF | 5.05/53.65 | 122 | 4.84 | |
| 5 | P04083 | Annexin A1 | Calcium ion binding | PMF | 5.85/38.71 | 132 | 2.94 | |
| 6 | P20839 | Inosine-5′-monophosphate dehydrogenase 1 | IMP dehydrogenase activity, metal ion binding | PMF, MS/MS | 5 | 6.43/55.41 | 116 | 2.17 |
| 7 | P12532 | Creatine kinase U-type | ATP binding | PMF, MS/MS | 3 | 7.31/43.08 | 89 | 3.15 |
| 8 | P04075 | Fructose-bisphosphate aldolase A | Fructose-bisphosphate aldolase activity | PMF | 8.30/39.42 | 142 | 4.14 | |
| 9 | P52565 | Rho GDP-dissociation inhibitor 1 | GTPase activator activity | PMF, MS/MS | 5 | 5.01/23.21 | 127 | 3.06 |
| 10 | P07195 | L-lactate dehydrogenase B chain | L-lactate dehydrogenase activity | PMF | 5.71/36.64 | 84 | 2.58 | |
| 11 | V9HW96 | Chaperonin containing TCP1, subunit 2 (Beta), isoform CRA_b | Molecular chaperonin | PMF | 6.01/57.49 | 133 | 2.09 | |
| 12 | P30041 | Peroxiredoxin-6 | Antioxidant activity | PMF, MS/MS | 8 | 6.00/25.03 | 93 | 3.56 |
| 13 | O00299 | Chloride intracellular channel protein 1 | Chloride channel activity | PMF, MS/MS | 9 | 5.09/26.92 | 122 | 4.19 |
| 14 | P30626 | Sorcin | Calcium channel regulator activity | PMF, MS/MS | 4 | 5.32/21.68 | 142 | 50.70 |
| 15 | P31949 | Protein S100-A11 | Calcium ion binding | PMF, MS/MS | 3 | 6.65/11.74 | 89 | 2.92 |
| 16 | P00558 | Phosphoglycerate kinase 1 | Phosphoglycerate kinase activity | PMF | 8.30/44.61 | 91 | 3.13 | |
| 17 | P06733 | Alpha-enolase | Phosphopyruvate hydratase activity | PMF, MS/MS | 22 | 7.01/47.17 | 123 | 2.17 (2.93)* |
| 18 | Q9NR45 | Sialic acid synthase | N-acetylneuraminate synthase activity | PMF | 6.29/40.31 | 97 | 2.04 | |
| 19 | P62837 | Ubiquitin-conjugating enzyme E2 D2 | Ubiquitin-protein ligase activity | PMF, MS/MS | 4 | 7.69/16.74 | 137 | 2.46 |
| 20 | P05787 | Keratin, type II cytoskeletal 8 | Scaffold protein binding | PMF, MS/MS | 9 | 5.52/53.71 | 152 | 2.03 |
| 21 | Q14320 | Protein FAM50A | Poly(A) RNA binding | PMF, MS/MS | 6 | 6.39/40.24 | 104 | 2.38 |
| 22 | P09972 | Fructose-bisphosphate aldolase C | Fructose-bisphosphate aldolase activity | PMF | 6.41/39.46 | 79 | 2.11 | |
| 23 | Q08752 | Peptidyl-prolyl cis-trans isomerase D | Hsp70 protein binding | PMF, MS/MS | 3 | 6.77/40.76 | 83 | 3.17 |
| 24 | P16422 | Epithelial cell adhesion molecule | Protein complex binding | PMF | 7.42/34.93 | 131 | 2.51 | |
| 25 | P37837 | Transaldolase | Monosaccharide binding | PMF, MS/MS | 4 | 6.36/37.54 | 89 | 2.04 |
| 26 | P11926 | Ornithine decarboxylase | Ornithine decarboxylase activity | PMF | 5.10/51.15 | 79 | 3.23 | |
| 27 | P09525 | Annexin A4 | Calcium ion binding | PMF, MS/MS | 2 | 5.83/35.88 | 169 | 4.24 |
| 28 | P06744 | Glucose-6-phosphate isomerase | Glucose-6-phosphate isomerase activity | PMF, MS/MS | 4 | 8.42/63.15 | 213 | 3.78 |
| 29 | P27797 | Calreticulin | Calcium ion binding | PMF, MS/MS | 4 | 4.29/48.14 | 228 | 2.22 |
| 30 | P05783 | Keratin, type I cytoskeletal 18 | Scaffold protein binding | PMF, MS/MS | 11 | 5.34/48.06 | 142 | 2.13 |
| Proteins with decreasing spot intensity | ||||||||
| 31 | P30101 | Protein disulfide-isomerase A3 | Cysteine-type endopeptidase activity | PMF, MS/MS | 7 | 5.98/56.78 | 103 | 0.32 |
| 32 | P28070 | Proteasome subunit beta type-4 | Threonine-type endopeptidase activity | PMF, MS/MS | 2 | 5.70/29.20 | 187 | 0.23 |
| 33 | Q99LB4 | Capping protein (Actin filament), gelsolin-like | Cell projection assembly | PMF | 6.47/38.77 | 109 | 0.29 | |
| 34 | Q9NNW7 | Thioredoxin reductase 2, mitochondrial | Thioredoxin-disulfide reductase activity | PMF | 7.24/56.51 | 93 | 0.43 | |
| 35 | O95782 | AP-2 complex subunit alpha-1 | Protein transporter activity | PMF, MS/MS | 7 | 6.63/107.5 | 167 | 0.41 |
| 36 | Q16082 | Heat shock protein beta-2 | Enzyme activator activity | PMF | 5.07/20.23 | 102 | 0.38 (0.52)* | |
| 37 | P42330 | Aldo-keto reductase family 1 member C3 | Androsterone dehydrogenase activity | PMF | 8.06/36.85 | 146 | 0.45 | |
| 38 | Q16553 | Lymphocyte antigen 6E | Epinephrine secretion | PMF | 8.06/13.51 | 129 | 0.48 | |
| 39 | P35232 | Prohibitin | Sequence-specific DNA binding RNA polymerase II transcription factor activity | PMF, MS/MS | 2 | 5.57/29.80 | 114 | 0.28 |
| 40 | Q92729 | Receptor-type tyrosine-protein phosphatase U | Beta-catenin binding | PMF | 6.46/16.24 | 92 | 0.21 | |
| 41 | P02649 | apolipoprotein E | Antioxidant activity | PMF | 5.65/36.15 | 83 | 0.31 | |
| 42 | Q15181 | Inorganic pyrophosphatase | Inorganic diphosphatase activity | PMF, MS/MS | 4 | 5.54/32.66 | 162 | 0.25 |
| 43 | P06576 | ATP synthase subunit beta, mitochondrial | Proton-transporting ATP synthase activity, rotational mechanism | PMF, MS/MS | 7 | 5.26/56.56 | 127 | 0.41 |
| 44 | P52597 | Heterogeneous nuclear ribonucleoprotein F | RNA binding | PMF, MS/MS | 3 | 5.37/45.67 | 215 | 0.46 |
Note: *The data in the brackets represent the diffenrential ratio obtained from Western blot analysis.
Figure 3Identification of sorcin by mass spectrometry analysis and database searching. (A) MS/MS spectrum of a doubly-charged peak at m/z 752.8. The corresponding peptide is identified as ITFDDYIACCVK (154–165). (B) MS/MS spectrum of a doubly-charged peak at m/z 490.8. The corresponding peptide is identified as LMVSMLDR (77–84), in which the methionine is oxidized. (C) Identification of sorcin by MS/MS analysis. The data were searched against SwissProt database through Mascot engine.
Figure 4Western blotting analysis of some of differentially expressed proteins. (A) Western blotting analysis of HSP70, HSP27, and enolase 1 between K562 cells and K562/A02 cells. The amount of total protein loaded was 20 μg per lane. Differential expression of the protein of interest between doxorubicin-resistant myelogenous leukemia cell line K562/A02 and its parental control cell line K562 is normalized to actin by probing the same membrane with a monoclonal antibody specific for the protein. (B) Western blotting analysis of HSP70 and HSP27 in K562 cells with and without 1 microgram/ml doxorubicin treatment for 2 hrs, respectively.